Journal
BIOMEDICINES
Volume 4, Issue 3, Pages -Publisher
MDPI
DOI: 10.3390/biomedicines4030014
Keywords
ADC; antibody-drug conjugate; resistance; monoclonal antibodies; cancer; immunotherapy
Categories
Funding
- NHMRC [1084178, 1087850, 1030469, 1075898]
- Cancer Australia
- Ludwig Cancer Research
- John T Reid Trusts
- Cure Brain Cancer Foundation
- La Trobe University
- Victoria Cancer Agency
- Operational Infrastructure Support Program by Victorian Government, Australia
- National Health and Medical Research Council of Australia [1084178, 1087850, 1075898] Funding Source: NHMRC
Ask authors/readers for more resources
Antibody-drug conjugates (ADCs) take advantage of the specificity of a monoclonal antibody to deliver a linked cytotoxic agent directly into a tumour cell. The development of these compounds provides exciting opportunities for improvements in patient care. Here, we review the key issues impacting on the clinical success of ADCs in cancer therapy. Like many other developing therapeutic classes, there remain challenges in the design and optimisation of these compounds. As the clinical applications for ADCs continue to expand, key strategies to improve patient outcomes include better patient selection for treatment and the identification of mechanisms of therapy resistance.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available